Literature DB >> 20818868

New therapies for castration-resistant prostate cancer.

Dan L Longo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20818868     DOI： 10.1056/NEJMe1006300

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  48 in total

Review 1.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Authors:  Luc Pilotte; Pierre Larrieu; Vincent Stroobant; Didier Colau; Eduard Dolusic; Raphaël Frédérick; Etienne De Plaen; Catherine Uyttenhove; Johan Wouters; Bernard Masereel; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  Methoxychalcone inhibitors of androgen receptor translocation and function.

Authors:  Yeong Sang Kim; Vineet Kumar; Sunmin Lee; Aki Iwai; Len Neckers; Sanjay V Malhotra; Jane B Trepel
Journal:  Bioorg Med Chem Lett       Date:  2012-01-21       Impact factor: 2.823

4.  Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy.

Authors:  Alberto Purwada; Ye F Tian; Weishan Huang; Kathleen M Rohrbach; Simrita Deol; Avery August; Ankur Singh
Journal:  Adv Healthc Mater       Date:  2016-04-21       Impact factor: 9.933

Review 5.  Dendritic-cell-based technology landscape: Insights from patents and citation networks.

Authors:  Xiangjun Kong; Yuanjia Hu; Zhifang Cai; Fengqing Yang; Qianru Zhang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  Management of metastatic castration-resistant prostate cancer: recent advances.

Authors:  Deborah Mukherji; Andrew Eichholz; Johann S De Bono
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

7.  Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

Authors:  Marijo Bilusic; Christopher R Heery; Philip M Arlen; Myrna Rauckhorst; David Apelian; Kwong Y Tsang; Jo A Tucker; Caroline Jochems; Jeffrey Schlom; James L Gulley; Ravi A Madan
Journal:  Cancer Immunol Immunother       Date:  2013-12-07       Impact factor: 6.968

Review 8.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Authors:  Steffen Rausch; Christian Schwentner; Arnulf Stenzl; Jens Bedke
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 10.  Critical appraisal of cabazitaxel in the management of advanced prostate cancer.

Authors:  Sumanta Kumar Pal; Przemyslaw Twardowski; Oliver Sartor
Journal:  Clin Interv Aging       Date:  2010-12-03       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.